A2A Pharmaceuticals, Inc. Announces Phase 1 Clinical Trial Advancements in TACC3 Inhibition Program Targeting Multiple Cancers ...Middle East

NEW YORK, Dec. 11, 2024 /PRNewswire/ -- A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies, today announced significant progress in its clinical studies exploring TACC3 (Transforming...

Read More Details
Finally We wish PressBee provided you with enough information of ( A2A Pharmaceuticals, Inc. Announces Phase 1 Clinical Trial Advancements in TACC3 Inhibition Program Targeting Multiple Cancers )

Also on site :

• Disney World Announces Opening Date for First Nighttime Parade in Nearly a Decade
• 'Law & Order' Fans Stunned by 'Girls Night Out' Photos of Mariska Hargitay and Kelli Giddish
• Mama June Shannon Quit Weight Loss Shots Cold Turkey—Here’s Why